VCA
GMAB icon

Verdence Capital Advisors’s Genmab GMAB Stock Holding History

Verdence Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,812
Closed -$229K – 351
2020
Q1 		$229K Buy
10,812
+969
+10% +$21.6K 0.07% 252
2019
Q4 		$220K Buy
+9,843
New +$215K 0.05% 285

Other funds holding GMAB

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Verdence Capital Advisors's GMAB Position: Q2 2020 in Review

Verdence Capital Advisors sold out of Genmab (GMAB) in Q2 2020, closing a stake of 10,812 shares — an estimated $229K sold.

Verdence Capital Advisors first reported a position in GMAB in Q4 2019 and held it in 2 quarters. The position peaked at $229K in Q1 2020. 174 funds tracked by Wall St. Rank hold GMAB as of Q2 2020.

  • Verdence Capital Advisors reported no remaining Genmab position as of Q2 2020 after selling out during the quarter.
  • Verdence Capital Advisors sold 10,812 Genmab shares in Q2 2020, an estimated $229K.
  • Verdence Capital Advisors first reported a position in Genmab in Q4 2019 and held it in 2 quarters.
  • Verdence Capital Advisors's Genmab position peaked at $229K in Q1 2020.
  • 174 funds tracked by Wall St. Rank held Genmab as of Q2 2020.

Based on Verdence Capital Advisors's 13F filing for Q2 2020, filed 11 Aug 2020.